
Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

Janssen presents one-shot COVID-19 vaccine data
Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...

Novel COVID antibody enters clinical testing
In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...

Rentschler Biopharma launches gene therapy subsidiary
Monoclonal antibody specialist Rentschler Biopharma SE is moving forward with the expansion of its geographic footprint and technological porttfolio....

Next-gen COVID-19 vaccine good in preclinical tests
In contrast to injectable vaccines, the nasal jab seems capablet to induce mucosal immunity which is crucial to eliminate the virus instead only...